Company news
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news
Ionis Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 8, 2025: Ionis to host investors and analysts for Innovation Day 2025
Press releases — page 2
Ionis to host investors and analysts for Innovation Day 2025
September 7, 2025
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
September 1, 2025
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
August 20, 2025
Ionis reports second quarter 2025 financial results and highlights progress on key programs
July 29, 2025
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
July 24, 2025
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
July 20, 2025
Ionis to hold second quarter 2025 financial results webcast
July 15, 2025
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
June 24, 2025
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
June 11, 2025
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
June 10, 2025
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 18, 2025
Ionis to host 2025 virtual Annual Meeting of Stockholders
May 5, 2025
Ionis reports first quarter 2025 financial results
April 29, 2025
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
April 29, 2025
Ionis to hold first quarter 2025 financial results webcast
April 15, 2025
Ionis to host expert panel discussion on sHTG
April 2, 2025
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
March 25, 2025
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
March 10, 2025
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
March 9, 2025
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
February 19, 2025
Ionis reports fourth quarter and full year 2024 financial results
February 18, 2025
Ionis to hold fourth quarter and full year 2024 financial results webcast
February 4, 2025
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
January 12, 2025
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
December 18, 2024
Ionis reports third quarter 2024 financial results
November 5, 2024
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
November 5, 2024
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
November 3, 2024
Ionis to hold third quarter 2024 financial results webcast
October 22, 2024
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
October 20, 2024
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
October 2, 2024
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
September 30, 2024
Ionis announces proposed public offering of common stock
September 8, 2024
Ionis announces pricing of $500.3 million public offering
September 8, 2024
Ionis reports second quarter 2024 financial results
July 31, 2024
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
July 21, 2024
Ionis to hold second quarter 2024 financial results webcast
July 18, 2024
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
July 17, 2024
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
July 7, 2024
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
June 24, 2024
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
June 17, 2024
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
June 16, 2024
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
May 30, 2024
Ionis to hold donidalorsen Phase 3 data webcast
May 27, 2024
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
May 22, 2024
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 15, 2024
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 15, 2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 15, 2024
Ionis to host 2024 virtual Annual Meeting of Stockholders
May 14, 2024
Ionis reports first quarter 2024 financial results
May 6, 2024